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Abstract
Background: Causal associations between microglia activation and β-amyloid (Aβ) accumulation during the
progression of Alzheimer’s disease (AD) remain a matter of controversy. Therefore, we used longitudinal dual
tracer in vivo small animal positron emission tomography (μPET) imaging to resolve the progression of the
association between Aβ deposition and microglial responses during aging of an Aβ mouse model.
Methods: APP-SL70 mice (N = 17; baseline age 3.2–8.5 months) and age-matched C57Bl/6 controls (wildtype
(wt)) were investigated longitudinally for 6 months using Aβ (18F-florbetaben) and 18 kDa translocator protein
(TSPO) μPET (18F-GE180). Changes in cortical binding were transformed to Z-scores relative to wt mice, and
microglial activation relative to amyloidosis was defined as the Z-score difference (TSPO—Aβ). Using 3D
immunohistochemistry for activated microglia (Iba-1) and histology for fibrillary Aβ (methoxy-X04), we measure
microglial brain fraction relative to plaque size and the distance from plaque margins.
Results: Aβ-PET binding increased exponentially as a function of age in APP-SL70 mice, whereas TSPO binding had an
inverse U-shape growth function. Longitudinal Z-score differences declined with aging, suggesting that microglial
response declined relative to increasing amyloidosis in aging APP-SL70 mice. Microglial brain volume fraction was
inversely related to adjacent plaque size, while the proximity to Aβ plaques increased with age.
Conclusions: Microglial activity decreases relative to ongoing amyloidosis with aging in APP-SL70 mice. The plaque-
associated microglial brain fraction saturated and correlated negatively with increasing plaque size with aging.
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Background
The progressive accumulation of senile plaques composed
of β-amyloid (Aβ) is a main pathological hallmark of
Alzheimer’s disease (AD), the most common dementing
disorder in the elderly. The Aβ accumulation promotes
synaptic loss and neuronal degeneration apparently by ac-
tivating microglia, the resident macrophages of the brain
[1–4]. In the healthy brain, microglia cells are long-lived
cells using highly motile processes to survey parenchymal
territory for the presence of pathogens and cell debris. In
addition, microglia secrete factors that support neuronal
survival and synaptogenesis [5]. In the early stages of AD,
microglia migrate towards amyloid deposits and express
certain cell-surface receptors to promote the clearance
and phagocytosis of Aβ [6–8]. Furthermore, deficits in
microglia activation favor accelerated amyloid deposition
[9]. However, it has been hypothesized that microglial re-
actions are overwhelmed by the massive Aβ deposition in
later AD stages [10, 11]. This suggestion is supported by
the finding that plaque-associated microglia ultimately
show decreased expression of Aβ-binding receptors,
which leads to a significant reduction in Aβ degradation
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by microglia in the aging brain [11]. Moreover, plaque-
associated microglial cells show a threefold higher mor-
tality rate compared to non-plaque-associated microglia
in vivo [12].
The use of small animal positron emission tomog-
raphy (μPET) with Aβ tracers enables longitudinal in-
vestigations of cerebral amyloidosis in rodents in vivo
[13, 14]. Confirmation of the hypothesis of a ceiling
effect in microglial reactions has been hampered by
the technical difficulty in following the fate of aging
microglial cells in living mice. The past decade has
seen the introduction of Aβ-μPET in rodents [15, 16],
using the same radioligands employed in the clinical
routine for the differential diagnosis of AD [17, 18]. A
series of PET radiotracers targeting the microglial
marker 18-kDa translocator protein (TSPO), formerly
known as the peripheral benzodiazepine receptor
(PBR) [19–23], has been developed in recent years.
The basal availability of TSPO binding sites is low in
the healthy living brain (21), such that local upregula-
tion presents a sensitive marker for the detection of
microglial activation in afflicted brain regions [24–26].
This is supported by findings of elevated TSPO expres-
sion in the hippocampus and the frontal, temporal, and
parietal cortices of postmortem AD brain [25, 27, 28].
Our group has recently established cross-sectional dual
tracer μPET imaging of Aβ and TSPO in transgenic AD
mouse models [29]. Given this background, we aimed
in the present longitudinal Aβ/TSPO double tracer
μPET study to explore the longitudinal association
between amyloidosis and microglial response during
aging of an amyloid mouse model in vivo. By using mice
with a range of baseline age, we were able to perform
correlation analysis with the longitudinal biomarker
progression over 7 months. Final immunohistochemistry
supported the interpretation of μPET results by mapping
of individual plaques and microglial cells.
Methods
Animals and study design
All experiments were carried out in compliance with the
National Guidelines for Animal Protection, Germany, and
with the approval of the regional animal care committee
(Regierung Oberbayern) and were overseen by a veterinar-
ian. Animals were housed in a temperature- and humidity-
controlled environment with a 12 h light–dark cycle, with
free access to food (Sniff, Soest, Germany) and water.
All experiments were performed in APP-SL70 mice,
a mouse-line produced by Roche (Basel, Switzerland),
(N = 17, baseline age: 3.2 to 8.5 months of age: 3.2 to
5.0 months (N = 4); 5.1 to 6.8 months (N = 6); and 6.9
to 8.5 months (N = 7)). First fibrillar Aβ deposits in this
mouse-line appear as early as 2.5 months of age,
similar to the mouse line used by Blanchard [30].
Congophilic plaques are observed starting from 5 to
6 months of age. Protein levels of Aβ40 and Aβ42 start
to increase from 3 months of age and range around
1 ng/mg brain at 6 months, 25 ng/mg brain at
9 months, and 90 ng/mg brain at 12 months of age.
μPET examinations (Aβ and TSPO) were performed in
a longitudinal design at baseline (0 months), follow-up
(+ 2.2 months/11 weeks) and terminal age (+
6.3 months/29 weeks). Serial μPET scans of both
tracers deriving from a total of 30 age-matched C57Bl6
mice (wt) served as control data. All mice were killed
after terminal scanning, followed by rapid brain re-
moval and performance of immunohistochemistry ana-
lyses. The study design is illustrated in Fig. 1.
Radiochemistry
Radiosynthesis of [18F]-GE180 was performed as previ-
ously described [23], with slight modifications [29].
This procedure yielded product with radiochemical
purity exceeding 98%, and molar activity of 1400 ± 500
gigabecquerel (GBq)/μmol at end of synthesis. Radio-
synthesis of [18F]-florbetaben was performed as
described earlier [16, 31].
μPET data acquisition, reconstruction and preprocessing
All μPET procedures followed an established standardized
protocol for radiochemistry, acquisition, and post-process-
ing [29, 32]. Mice were anesthetized with isoflurane (1.5%,
delivered at 3.5 l/min) and placed in the aperture of the
Siemens Inveon DPET (Siemens, Knoxville, USA), as de-
scribed previously [33]. In brief, we made TSPO-μPET
emission recordings during 60–90 min (p.i.) per image of
[18F]-GE180 (11.2 ± 1.5 megabecquerel (MBq))
beta-amyloid-μPET emission recordings during 30–
60 min p.i. of [18F]-florbetaben (10.8 ± 1.5 MBq). All im-
ages were spatially normalized using automatic algorithms
and tracer specific templates [32].
μPET data analyses
All μPET analyses were performed with PMOD (V3.5,
PMOD technologies, Basel, Switzerland). Normalization
of emission images to standardized uptake value ratio
(SUVR) images was performed using a previously vali-
dated white matter reference region [29, 32]. A target
volume of interest (VOI) was placed in the bilateral
frontal cortex (46 mm3) and SUVRCTX/WM values were
extracted for each individual APP-SL70 and wt mouse
at the serial imaging time points for both tracers.
Differences of TSPO- and Aβ-μPET SUVR between ter-
minal and baseline time points were calculated as per-
centage change (Δ%). Z-scores of the TSPO- and
Aβ-μPET tracer uptake in individual APP-SL70 mice
were calculated by normalization to age-matched wt
mice. To this end, the mean uptake in age-matched wt
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mice was subtracted from the individual value in
APP-SL70 mice (APP-SL70INDIVIDUAL - wtMEAN) and
the resulting difference divided by the corresponding
standard deviation for wt mice to generate an individ-
ual Z-score value.
Z−score ¼ APPSL70 INDIVIDUALð Þ−wt MEANð Þ
wt SDð Þ
To establish a readout of microglial activity relative to
fibrillary amyloidosis we calculated Z-score differences
between TSPO- and Aβ-μPET. Z-scores deriving from
the same imaging time point of individual mice (gap
0.35 ± 1.62 weeks).
Z−score difference ¼ Z−score TSPO−μPETð Þ
−Z−score Aβ−μPETð Þ
Immunohistochemistry: acquisition and image analysis
Brains intended for immunohistochemistry were fixed
by immersion in 4% paraformaldehyde at 4 °C for 15 h.
Two representative 50-μm-thick slices per animal were
then cut in the axial plane using a vibratome (VT
1000 S, Leica, Wetzlar, Germany). Free-floating sec-
tions were permeabilized with 2% Triton X-100 over-
night and blocked with I-Block™ Protein-Based
Blocking Reagent (Thermo Fischer Scientific, Wal-
tham, USA). We obtained immunofluorescence label-
ling of microglia using an Iba-1 primary antibody
(Wako, Richmond, USA) with a dilution of 1:200 in
I-Block™ and the A-21244 secondary antibody (Invitro-
gen, Carlsbad, USA) with a dilution of 1:500 in
I-Block™. For histological staining against fibrillar Aβ,
we used methoxy-X04 (TOCRIS, Bristol, United King-
dom) with a dilution of 0.01 mg/ml. The unbound dye
was removed in three washing steps with PBS, and the
slices were then mounted on microscope slides with
fluorescent mounting medium (Dako, Santa Clara,
USA). Images were acquired with a LSM 780 confocal
microscope (Zeiss, Oberkochen, Germany) equipped
with a 40x/1.4 oil immersion objective. The excitation
wavelength for Iba-1 detection was 633 nm and
emission was detected from 638 to 755 nm. For
methoxy-X04, the excitation wavelength was 405 nm
and emission was detected from 403 to 585 nm for
each brain slice. We acquired three-dimensional 16-bit
data stacks of 2048 × 2048 × 120 pixels from five differ-
ent positions in the frontal cortex at a lateral reso-
lution of 0.17 μm/pixel and an axial resolution of
0.4 μm/pixel. To quantify Iba-1 positive brain volume
fraction, hereinafter referred as microglia brain fraction, as
well as plaque density and size, we utilized custom-written
Matlab software (MathWorks, Natick, USA). The detailed
method was described previously [34].
Local background subtraction was used to diminish
intensity variations between different stacks. Subse-
quently, microglia cells were identified by applying
the 90th percentile as minimal-intensity threshold.
Noise was excluded by applying a connected compo-
nent analysis excluding patches of contiguous voxels
smaller than 1 μm3. Analyses were performed by an
operator who was blind to the μPET results.
Statistics
The associations between μPET readouts (Δ%, Z-score,
Z-score difference) and age were characterized by
applying linear, logarithmic, and quadratic regression
analyses as implemented in SPSS (SPSS Version 24,
IBM SPSS Software, IBM, Armonk, New York). In
cases with several statistically significant fits (p < 0.05),
Fig. 1 Schematic illustration of the study design. In vivo β-amyloid small animal positron emission tomography (Aβ-μPET) and 18 kDa translocator
protein (TSPO)-μPET imaging was performed in a longitudinal design with baseline examination at 0 months, follow-up at + 2.2 months, and terminal
examination at + 6.3 months in the Alzheimer’s disease (AD) mouse model, APP-SL70. Molecular validation of μPET results was performed
via immunohistochemistry in mid- (11.4 to 12.7 months) and late-aged (13.6 to 15.3 months) APP-SL70 mice after the final μPET-scan.
Custom-written Matlab software was used to quantify histological results
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the best curve fitting model was determined by apply-
ing the Akaike Information Criterion (AIC) [35]. If the
AIC proved indifferent between two models, we chose
the one with the higher R2 value. Statistics of histo-
logical analyses were calculated in Prism 7.01 (Graph-
Pad Software, San Diego, CA, USA). Statistical
comparison of the microglia fraction between different
plaque radii was performed for the highest microglia
occupancy in the vicinity to the plaque border [6].
Data was tested for normal distribution using the
D’Agostino and Pearson omnibus test. Intergroup com-
parisons were performed using the two-tailed unpaired
Student’s t test. For correlation of plaque size and
microglia brain fraction, the variables were compared
across groups using one-way analysis of variance
(ANOVA). All specifications of n state the number of
biological replicates. All results are presented as mean
± standard error of mean (SEM).
Results
Microglial response saturates relatively to ongoing
amyloidosis during aging
First, we analyzed serial changes of TSPO and fibrillar
amyloidosis by dual tracer μPET to characterize the
AD mouse model through molecular imaging. Both
TSPO-μPET (+ 2.8 ± 2.4% per month) and Aβ-PET sig-
nals (+ 2.9 ± 2.5% per month direct comparison of
TSPO-PET and Aβ-PET increase rates: p = 0.897) in-
creased strongly during aging of individual APP-SL70
mice. At late time points, the two markers were dis-
tinctly elevated when compared to wt mice (Fig. 2a–c)
and there was a strong direct association between
SUVR values of both PET tracers (quadratic fit, R =
0.90, p < 0.001). However, the percentage change of
PET SUVR between baseline and + 6.3 months as a
function of starting age in APP-SL70 mice showed an
inverted U-shape for TSPO binding (quadratic fit, R =
0.69, p = 0.014, Fig. 2d) but a linear positive association
for amyloidosis (linear fit, R = 0.50, p = 0.048, Fig. 2e).
Thus, increases of microglial activity in aged APP-SL70
mice tended to reach a plateau whereas amyloidosis
continued to progress even at late follow-up. Given the
differences by tracer in μPET alterations as functions
of age, we aimed to compare directly the longitudinal
time courses of TSPO activity and amyloidosis. To this
end, we calculated standardized Z-scores for individual
mice and for both tracers based on findings in
age-matched wt controls. By this approach, we found
the expected strong increases with age for TSPO activ-
ity (quadratic fit, R = 0.68, p < 0.001; Fig. 3a) and fibril-
lar amyloidosis (quadratic fit, R = 0.86, p < 0.001,
Fig. 3b). Next, Z-score differences (TSPO—Aβ) for all
serial imaging time points were introduced as a measure
of microglial activity relative to fibrillar amyloidosis.
Importantly, we observed a decreasing Z-score difference
as a function of age in APP-SL70 mice (quadratic fit, R =
0.66, p < 0.001, Fig. 3c), which clearly revealed that the
microglial response to ongoing amyloid deposition is rela-
tively attenuated at the later ages ((Z-score difference < 0)
≥ 12.2 months of age) of the mouse model. Notably, this
effect was not only observed at the group level but was
also distinguishable in single animals (Fig. 3d).
Plaque-associated microglial brain fraction decreases with
increasing plaque size during aging
To confirm and extend observed in vivo results,
methoxy-X04 staining of fibrillar Aβ as well as Iba-1
staining of microglia were performed in mid- (11.4 to
12.7 months) and late-aged (13.6 to 15.3 months)
APP-SL70 mice after the final μPET-scans. In line with
previous studies, our immunohistochemical analysis
showed that the observed increase in the Aβ-μPET sig-
nal is indicative of plaque growth rather than increased
plaque density (Fig. 4a, b). In late-aged APP-SL70,
mice the mean plaque radius was significantly elevated
by approximately 3 μm compared to that in mid-aged
mice (t(14) = 5.86, p < 0.0001, two-tailed Students t test,
Fig. 4b), whereas plaque density in both age groups
remained unchanged at approximately 3600/μm3 (t(14)
= 0.33, p = 0.746, two-tailed Students t test, Fig. 4c).
Furthermore, plaque size distribution analysis showed
a shift towards larger radii in late-aged compared to
mid-aged transgenic mice (Fig. 4a).
Microglia proliferation in plaque-free areas and their
migration towards Aβ plaques has already been shown
to occur in AD model mice [12], which results in an
increased number of microglial cells surrounding
amyloid deposits [36]. However, our standardized
μPET analysis revealed a decrease of the TSPO signal
in direct relation to the increasing amyloid signal with
aging (Fig. 3c). To assess the molecular relationship
between plaque growth and microglial brain fraction,
we applied custom-written MATLAB cluster analysis
for automated morphological detection by applying the
90th percentile as the minimal intensity threshold for
identifying microglial cells. We analyzed a total of
1312 plaques ranging in radius from 3 μm to 30 μm
and identified their associated microglial cells via im-
munofluorescence. Representative plaques of several
sizes are illustrated in Fig. 5. Interestingly, when we
calculated the mean volume occupied by Iba1-positive
microglia in consecutive 1-μm-thick layers around the
plaque border up to 20 μm distance, we observed a
maximum of microglial brain fraction near small pla-
ques (radii between 3 and 4 μm), while the microglia
brain fraction decreased with increasing plaque radius
(F(5,16) = 11.87, p < 0.0001, one-way ANOVA, (Fig. 4d,
e, Fig. 5). We conclude that the observed age-related
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decrease of the TSPO-μPET signal relative to the
Aβ-μPET signal was likely driven by a decrease in the
microglial brain fraction around large plaques, which
came to predominate in late-aged APP-SL70 mice
(Fig. 4b).
Microglial brain fraction in the plaque-free cortical brain
parenchyma of APP-SL70 mice was less compared to wt
mice
It is well acknowledged that microglial cells are essen-




Fig. 2 Microglial response increased but saturated relative to ongoing amyloidosis during aging. Plots show cortical Standardized Uptake Value
Ratio (SUVR) of [18F]-GE180 (TSPO-activity) (a) and [18F]-florbetaben (amyloidosis) (b) in APP-SL70 mice at different ages (B) APP-SL70 indicate increasing
cortical amyloidosis and 18 kDa translocator protein (TSPO) binding during aging (c). Percentage change for both PET tracers between baseline and +
6.3 months as a function of baseline age in APP-SL70 mice and wt reveal an inverted U-shape for TSPO activity (quadratic fit, R = 0.69, p= 0.014 (d) but a
linear positive association for amyloidosis in APP-SL70 (linear fit, R= 0.50, p= 0.048 (e). N= 17
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rapidly proliferate in response to a wide range of cen-
tral nervous system insults [37, 38]. In this context, a
recent study of microglial turnover and proliferation in
AD showed comparable rates of proliferation and loss
for plaque-associated microglial cells indicating a
steady-state, while non-plaque-associated microglial
cells showed a threefold higher proliferation rate. In
contrast, wt mice show only moderate rates of micro-
glial cell proliferation and loss [12]. In the present
study, we observed an increase in microglial brain frac-
tion in APP-SL70 mice only in proximity to the plaque
border, starting at a maximal distance of 20 μm
(Fig. 6a). Surprisingly, we detected a significantly lower
microglial brain fraction distant to plaques in the
APP-SL70 mice compared to the microglial brain frac-
tion in wt mice (t(25) = 2.18, p < 0.05, two-tailed Stu-
dents t test, Fig. 6b). It is well-known that microglial
cells are activated by Aβ deposits and actively migrate
towards the plaque within 1 to 2 days after the initial
formation of an amyloid deposit [6, 39]. Regarding the
threefold higher proliferation rate of non-plaque-asso-
ciated microglial cells, the net microglial loss distal to
plaques in APP-SL70 compared to wt mice, while sur-
prising, is conspicuous in our double-labelling studies
(Fig. 6c).
Discussion
We present the first longitudinal in vivo dual tracer
μPET study aiming to directly compare the time
courses of microglial activation and fibrillar amyloid-
osis with age in a transgenic amyloid mouse model.
Our results clearly indicate that both biomarkers
increase with age, but that microglial activation is dis-





Fig. 3 Standardized μPET analysis (Z-scores) TSPO activity and amyloidosis. Standardized TSPO activity (a; quadratic fit, R = 0.68, p < 0.001) and
standardized fibrillar amyloidosis (b; quadratic fit, R = 0.86, p < 0.001) indicate an increase with aging. The direct comparison of both standardized
tracer signals reveals a decrease in the Z-score differences (TSPO—Aβ) with aging (c; quadratic fit, R = 0.66, p < 0.001). d Exemplary findings of a
single APP-SL70 mouse show that microglia response is overwhelmed by ongoing amyloid deposition. N = 16
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saturate relative to amyloidosis, which continues to
progress. Detailed immunohistochemical analyses
revealed a significant decrease of microglial brain frac-
tion around amyloid plaques with increasing plaque ra-
dius to be the cellular correlate of our in vivo μPET
findings. Moreover, we found that the microglia brain
fraction in the plaque-free brain parenchyma of
APP-SL70 mice was lower than in wt mice. This deple-
tion of microglial cells distal to plaques is likely related
to the massive microglial migration towards zones of
fibrillar Aβ deposition [6, 39].
With this serial in vivo study, we aimed to investigate
longitudinal relationships between microglial activa-
tion and amyloidosis during the life course of the
APP-SL70 AD mouse model. We performed
dual-tracer small animal μPET examinations with the
novel tracer [18F]-GE180 for TSPO and [18F]-florbeta-
ben for fibrillar amyloidosis, in conjunction with im-
munohistochemical analyses after the final imaging
studies. To enable a reliable comparison of the relation-
ship between the two μPET readouts, we took pains to
develop a standard procedure for quantification, entailing
a biphasic calculation method: First, we calculated
standardized tracer specific Z-scores of individual mice
at different time points by considering mean and
standard deviation values of age-matched wt mice. We
next calculated differences between TSPO- and
Aβ-μPET Z-scores as a measure of microglial activa-
tion relative to fibrillar amyloidosis. We deemed this
calculation of a difference score to be more reliable
than a ratio method, as values close to zero would po-
tentially have distorted the results at the onset of fibril-
lar amyloidosis in young mice. The two radioligands
have different sensitivities for their specific targets,
resulting in distinct detection thresholds unequal mag-
nitudes of signal alterations during the progression of
the AD model. To address these issues, we used the
standardized Z-score calculation as our main endpoint.
In fact, our analysis showed positive Z-score differ-
ences at early ages of APP-SL70 mice, which suggest
that microglial activation precedes fibrillar amyloidosis
at the onset of amyloid pathology. However, even with
standardized Z-scores, there remains some possibility
that this effect may be related to a higher sensitivity of
A B C
D E
Fig. 4 Molecular elucidation of in vivo μPET findings by terminal immunohistochemistry. a Frequency distribution of plaque radii in mid-aged
(11.4 to 12.7 months) and late-aged (13.6 to 15.3 months) APP-SL70 mice. The mean plaque radius (b) is significantly higher in the late-aged
cohort when compared to mid-aged APP-SL70 mice (p < 0.0001, two-tailed Student’s t test), whereas the plaque density (c) did not indicate
changes during aging > 12 months in APP-SL70 mice (p = 0.746, two-tailed Student's t test). d Correlation of microglial brain fraction with
distance to plaque border and plaque size. Each profile represents the change of microglial brain fraction with distance to the border of plaques
with defined radius. e Microglial brain fraction in the vicinity to the plaque border (radius 1 μm) decreased significantly with increasing plaque
radius (one-way ANOVA, F(5,16) = 11.87, p < 0.0001). Data presented as mean ± SEM; n = 7–9 mice
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the TSPO ligand to its target compared to the applied
Aβ tracer. In contrast, due to its baseline dependency,
the longitudinal decrease of the Z-score difference to-
wards late ages is a rather compelling readout unlikely
to be biased by possible tracer sensitivity differences.
Furthermore, ceiling effects are unlikely as far higher
magnitudes of TSPO activation and amyloidosis can be
detected with these tracers in other circumstances [31,
40]. Thus, our serial dual tracer μPET imaging proves
that microglial activation saturates during an ongoing
fibrillar amyloid deposition in this mouse model (Figs. 2
and 3). Our PET findings are absolutely in line with a
recently observed plateau during TSPO PET imaging
in aged APP23 mice by the same radioligand [41]. The
results are also in line with findings for other bio-
markers of microglial function, i.e., the peak in sTrem2
levels in cerebrospinal fluid of patients with mild cog-
nitive impairment [42], followed by a drop in patients
who have converted to dementia [43]. Even more im-
portantly, computed longitudinal courses of sTrem2 in
individuals with dominantly inherited AD decrease
after symptom onset whereas amyloid deposition con-
tinues to progress [44], thus concurring with the pres-
ently observed relations between TSPO expression and
fibrillar amyloidosis in aging APP-SL70 mice.
Although an important strength of μPET lies in its
fitness for longitudinal monitoring and target quantifi-
cation, molecular imaging has limitations in spatial
resolution and in its applicability for resolving mech-
anistic processes. For this reason, we supplemented
μPET with a detailed immunohistochemical study of
activated microglia and histological staining of fibrillar
Aβ, which together supported automatized volumetric
computations. Our data clearly indicate that microglia
fraction adjacent to plaques declines with increasing
plaque size (Fig. 4d). Given that plaque size but not
density increases with advanced age (Fig. 4b, c), it
seems obvious that the microglial activity must de-
crease relative to fibrillar amyloidosis over time. We
validated these findings by comparing mid- and late
aged APP-SL70 groups, concluding that the decreas-
ing microglial brain fraction with increasing plaque
size is consistent with our μPET results in vivo. Since
a recent study showed that brain location of microglia
is a relevant factor for its morphological classification
[45], our specific analysis of frontal cortical microglia
cells in wt and APP-SL70 mice seems appropriate as
it matched to the regional PET analysis.
So far, it remains unclear when and why microglial
activity decreases adjacent to plaques. It is known that
Fig. 5 Microglial brain fraction was maximal at small plaques. β-amyloid plaques of radius increasing from 3 to 30 μm are illustrated according to
their size (white numeral in upper left corner). Each pane shows Methoxy-X04 stained plaque (cyan) together with the Iba-1 immunosignal (magenta).
Scale bar 40 μm
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microglia migrate within 1–2 days towards newly
formed amyloid deposits, where they promote the
clearance and phagocytosis of Aβ by expressing certain
cell-surface receptors [6–8]. However, during disease
progression, plaque-associated microglial cells show a
decrease in fiber mobility [46], lower expression of
Aβ-binding receptors [11], and moreover also show a
threefold higher mortality rate compared to non-
plaque associated microglial cells [12]. Nonetheless,
the same in vivo study reported a threefold higher pro-
liferation rate of microglia distal to plaques in AD
compared to wt mice, suggesting that new microglial
cells migrate from the periphery to the plaque border
[12]. However, we observed even lower microglial
brain fraction distal to plaques of aged APP-SL70 mice
compared to wt animals (Fig. 6). We conclude that
the rate of microglia cell migration towards Aβ depo-
sitions in APP-SL70 mice eventually exceeds the rate
of proliferation of microglia cells staying in the
peripheral zone. With aging, this potentially leads to
an exhaustion of microglial cells for migration to-
wards Aβ depositions and, together with the increased
rate of microglial cell loss around plaques [12], this
may explain the observed decrease in microglia brain
fraction with increasing plaque radius.
As a limitation of this study, we note that the amyl-
oid tracer does not distinguish soluble and oligomeric
Aβ. Thus, we cannot disentangle if there is a stronger
association between microglia and soluble or oligo-
meric proportions of Aβ, which could show different
growth rates with aging. Furthermore, given the nature
of our longitudinal PET design, we were not able to
acquire immunohistochemistry from mice at younger
ages but instead focused on the late stage of the
disease. Proliferation rates, mortality, and spatial distri-
bution of microglia during their whole life cycle should




Fig. 6 Microglial brain fraction decreased in the plaque-free cortical brain parenchyma of APP-SL70 mice. a Microglial brain fraction as a function
of the distance to the plaque border in APP-SL70 mice (black line) when compared to the mean microglial brain fraction in wildtype (wt) mice
(dotted blue line). b Direct comparison of microglial brain fraction of APP-SL70 mice (> 30 μm from plaque borders) and wt mice (mean).
Microglial brain fraction is significantly reduced compared to wt mice (p < 0.05, two-tailed Student’s t test). c Iba-1 immunofluorescence staining
in a wt mouse aged 16 months in comparison to a double staining of Iba-1 and methoxy-X04 stained plaque in APP-SL70 mouse aged
15 months. Data are presented as mean ± SEM; n = 10–17
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Conclusion
Taken together, findings of this preclinical study in
transgenic mice reveal the individual trajectories of
microglial activation in relation to Aβ deposition, thus
providing important information about the staging of
AD-like pathology, which could guide human clinical
research. The translation of findings in animal models
to human disease is challenging, but the strong bidir-
ectional translational science potential of μPET
findings to clinical PET holds great promise to dramat-
ically advance our understanding of AD.
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